A Phase II Study Evaluating Intranasal GSK256066 and Azelastine Hydrochloride in Subjects With Seasonal Allergic Rhinitis
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
This study is an 8 day, randomised, double blind, 2-way crossover trial of repeat doses of
intranasal GSK256066 and azelastine hydrochloride in the Vienna Challenge Chamber in subjects
with seasonal allergic rhinitis (SAR). Laboratory safety assessments, 12-lead
electrocardiograph (ECG), vital signs and adverse event enquiries will be made throughout the
study. Nasal examination, symptom scores, and allergen challenge assessments will also be
performed at various time points throughout the study.